What are the clinical features, diagnostic criteria, and management recommendations for HbH disease (α‑thalassemia with three α‑globin gene deletions)?

HbH Disease: Clinical Features, Diagnosis, and Management

HbH disease is a form of α-thalassemia caused by deletion or dysfunction of three α-globin genes, resulting in moderate to severe hemolytic anemia with variable transfusion requirements; management centers on iron chelation therapy for those with iron overload, with transfusions reserved for symptomatic anemia or hemolytic crises.

Clinical Features and Pathophysiology

HbH disease results from impaired α-globin chain production, leading to excess β-globin chains that form unstable β4 tetramers (Hemoglobin H). This causes:

• Moderate to severe hemolytic anemia with hemoglobin levels typically 9-10 g/dL in steady state 1
• Ineffective erythropoiesis and chronic hemolysis
• Splenomegaly of variable degree
• Microcytic, hypochromic red blood cells with marked size variation 2

Genotype-Phenotype Correlation

Critical distinction: Non-deletional mutations cause significantly more severe disease than deletional mutations 3, 4:

• Deletional HbH disease (--/-α): Milder phenotype, transfusions uncommon, primarily preventative management 5
• Non-deletional HbH disease (e.g., HbH Constant Spring, --/αCSα): More severe anemia, approximately one-third require regular transfusions, greater risk of complications 5, 1
• Patients with --SEA/αCSα or --SEA/αQSα genotypes show the highest proportion of severe and moderate anemia 4

Acute Complications

Hemolytic crises frequently develop during or after acute infections with high fever, causing:

• Precipitous hemoglobin drops
• Risk of shock or renal shutdown
• Requires urgent intervention 1

Diagnostic Approach

Laboratory Findings

1. Complete blood count:

   • Decreased hemoglobin concentration
   • Reduced mean corpuscular volume (MCV)
   • Peripheral smear: microcytic hypochromic cells, enlarged central pallor, occasional oval cells 2

2. Hemoglobin electrophoresis/HPLC:

   • Presence of HbH (β4 tetramers)
   • Low HbA2 levels (distinguishes from β-thalassemia) 2

3. Genetic testing:

   • Gap-PCR for common deletions
   • Reverse dot blot hybridization for mutation detection
   • Multiplex ligation-dependent probe amplification (MLPA) and sequencing for complex cases 4, 6

Diagnostic pitfall: HbH disease may present with only mild symptoms and be diagnosed late, particularly in elderly patients with deletional mutations 7. Comprehensive judgment combining clinical symptoms and laboratory results is essential 2.

Management Strategies

Transfusion Management

Do NOT routinely transfuse patients with stable HbH disease. Most patients tolerate steady-state hemoglobin of 9-10 g/dL well 1.

Transfuse only when:

• Symptomatic anemia develops
• Hemolytic crisis occurs
• Hemoglobin drops significantly below baseline
• Non-deletional HbH with severe symptoms (approximately one-third of cases) 5

Iron Chelation Therapy

This is the cornerstone of management for transfusion-dependent patients 8:

First-line options:

• Deferoxamine: 40 mg/kg/day subcutaneous infusion for 8-12 hours nightly, 5-7 nights weekly 8
• Deferasirox (Exjade): Oral iron chelator approved for secondary iron overload due to ineffective erythropoiesis 8

Target: Reduce hepatic iron concentration (HIC) to <15,000 μg/g dry weight to significantly reduce risk of clinical disease 8

Monitoring: Unlike hereditary hemochromatosis, ferritin levels can be misleading in secondary iron overload. HIC measurement (via MRI or liver biopsy) provides accurate quantitative monitoring 8

Splenectomy

Splenectomy is NOT recommended despite significant hemoglobin elevation post-procedure, because most patients do well with their steady-state hemoglobin levels 1. The risks outweigh benefits in the majority of cases.

Preventative Measures

• Avoid iron supplementation unless true iron deficiency is documented
• Avoid vitamin C supplements (increases iron absorption) 8
• Avoid raw shellfish (risk of Vibrio vulnificus infection in iron-overloaded patients) 8
• Prompt treatment of infections to prevent hemolytic crises 1

Monitoring Requirements

For transfusion-dependent patients:

• Regular assessment of iron overload (ferritin, HIC via MRI)
• Cardiac function monitoring (iron cardiomyopathy risk) 9
• Hepatic function and surveillance
• Endocrine function (growth, thyroid, glucose metabolism)
• Bone health assessment

Curative and Emerging Therapies

Hematopoietic stem cell transplantation (HSCT) is the only curative option but is typically reserved for severe, transfusion-dependent cases given the risks 10.

Emerging therapies under investigation include:

• Luspatercept (for ineffective erythropoiesis)
• Gene therapy approaches
• Hydroxyurea in selected cases 10

Key Clinical Pitfalls

1. Do not assume all HbH disease is mild - non-deletional mutations require intensive management
2. Do not perform splenectomy routinely - reserve for exceptional circumstances
3. Do not rely solely on ferritin for iron monitoring in transfused patients - use HIC measurement
4. Do not delay chelation in transfusion-dependent patients - iron overload complications are preventable
5. Recognize hemolytic crises early - fever and infection trigger acute decompensation requiring urgent intervention